BioMarin's Amicus Integration Propels Diversification and Raises Peak-Sales Bar

Enzyme therapy acquisition adds two $1B+ products; VOXZOGO holds its own against first U.S. competitor.

BMRN · Earnings Call · 2026-08-06

A Transformative Second Quarter

The second quarter of 2026 marked a strategic inflection point for BioMarin. The close and early integration of Amicus Therapeutics didn't just add two high-growth products—it reframed BioMarin as a diversified rare-disease leader, rather than a one-product (VOXZOGO) story. Management labeled it a standout quarter: “BioMarin delivered a standout second quarter, combining strong growth to nearly $1 billion in revenue, with the successful close in integration of Amicus.” — Alexander Hardy, President and Chief Executive Officer · 2026-08-06 That revenue figure of $990 million is a 20% year-over-year jump, but the more important shift is internal: the portfolio now includes GALAFOLD and the Pompe combination, each carrying $1B+ peak potential.

Financial details underscore both the magnitude and the cost of the transformation. Total revenue hit $990M, but acquisition financing and integration costs compressed margins. Total revenue growth is healthy; operating income fell 63% YoY as interest expense and Amicus operating costs kicked in. CFO Brian Mueller clarified the interest burden will be roughly $200M annually—a necessary bridge to the $1.4B and $1.2B peak sales targets.

Amicus Begins to Pay Off

The integration of Amicus is progressing faster than Wall Street modeled. Management shared estimated peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI+OPFOLDA, and raised the annual synergy target to $220 million by 2028. More striking, they pulled forward the deleveraging timeline by a year. In the Q&A, CFO Brian Mueller said: “We pulled forward our leverage target by approximately one year... we're not only delivering on the potential of this transaction, but exceeding it.” — Brian R. Mueller, Executive Vice President · 2026-08-06 This is the kind of execution that builds long-term credibility. The Amicus business also brought BMN 820, a late-stage renal pipeline asset, further strengthening the combined R&D portfolio.

Earlier this year, CFO Brian Mueller had set the stage for these disclosures, noting the company would provide longer-term metrics after closing: “That is why we are going to wait until Q2 to give this additional update... it will include a number of details and metrics about the long-term potential.” — Brian Mueller, CFO · 2026-05-04 That promise has now been fulfilled.

VOXZOGO Defends Its Turf

The other major narrative is VOXZOGO's resilience against its first U.S. competitor. With six months of competition behind it, 90% of patients remain on therapy. Management was direct about the impact: “We've seen approximately 10% of patients switch. That translates to less than 100 patient switches in the approximately six months since they have been approved.” — Alexander Hardy, President and Chief Executive Officer · 2026-08-06 The under‑two age group (where BioMarin has exclusive label access) is driving new starts, and full‑year guidance was raised to at least $1 billion.

Above all, the competitive result reinforces the strength of BioMarin's evidence base. Post‑closing commentary in May had already telegraphed the confidence, with Alexander Hardy saying: “the opportunities and the opportunities for us to drive synergies on the top line as well as synergies in terms of the way that we operate are tremendous.” — Alexander Hardy, CEO · 2026-02-23 That was promised; now it is being delivered.

Pipeline and Portfolio

BioMarin continues to invest beyond the Amicus assets. It filed an sNDA for VOXZOGO in hypochondroplasia, with a PDUFA in 2027, and anticipates readouts from BMN 333, BMN 401, and others. The company renamed its Enzyme Therapies unit to Metabolic Conditions, reflecting the broader scope. The commercial update in the prepared remarks highlighted the progress:

GALAFOLD delivered broad-based patient growth across both established and newer markets... For POMBILITI + OPFOLDA, we continue to add patients... both brands maintained commercial momentum while we rapidly integrated.
Cristin Hubbard, Executive Vice President · 2026-08-06

The Pombility and Opfolda franchise grew over 65% on a pro‑forma basis, demonstrating immediate organic traction. With three potential $1B+ products and a broad metabolic franchise, BioMarin has effectively hedged its dependence on a single molecule.

Investors have rewarded the shift—BMRN is up nearly 24% over the past 90 days. Still, the stock trades below its 2015 peak, and the market is waiting to see if the margin recovery materializes as synergies roll out. The quarter answered a key question: BioMarin's integration playbook works.